Formulary e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Formulary e-News
|
|
 |
|
 |
Survey |
|
Last month's survey results:
Fingolimod (Gilenya) was recently FDA approved in the treatment of relapsing remitting multiple sclerosis (RRMS). How is your health system covering or planning on covering this new oral disease-modifying therapy (DMT)?
We will be/are covering it only for patients who have failed injectable DMTs (both in the interferon class and glatiramer acetate). 27%
We will be/are covering it only for patients who have failed injectable DMTs (either an interferon or glatiramer acetate). 0%
We will be/are covering it for patients that meet certain criteria. However, the main criteria does not have to be failure of an injectable DMT. 27%
We will be/are covering it for patients with a new diagnosis of RRMS only. 0%
We will not be covering it at all until more data is available. 9%
We have not yet decided how to cover this product. 36%
|
|
This month we would like to know...
|
|
With several proton pump inhibitors now available OTC, what do you believe is the most appropriate coverage for this class of agents within managed care drug benefit programs?
1) No coverage should be provided for OTC or prescription products under the drug benefit.
2) Coverage of prescription products only under the drug benefit without restriction.
3) Coverage of prescription products only under the drug benefits with restrictions (eg, step therapy).
4) Coverage of both prescription and OTC products under the drug benefit without restriction.
5) Coverage of both prescription and OTC products under the drug benefit with restriction (eg, step therapy).
|
|
|
FDA recently issued warning letters to companies that manufacture and market over-the-counter products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylocococcus aureus. Read full article. |
 |
To confirm your e-newsletter subscription, click here.
To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff
|
Two of the most commonly used treatments for neovascular AMD, ranibizumab (Lucentis, Genentech), approved in 2006 by FDA, and the other commonly used 'off-label,' bevacizumab (Avastin, Genentech), resulted in similar improvements in visual acuity, according to a new randomized controlled trial published in NEJM. Read full article. |
|
|
The lipid-lowering efficacy and tolerability of bile acid sequestrants suggest that these agents have potential in pediatric patients with familial hypercholesterolemia, according to a recent literature review from the University of Chicago Pritzker School of Medicine. Read full article.
|
|
The American Heart Association recently released its updated cardiovascular disease prevention guidelines for women. The guidelines emphasize practical medical advice that works in the "real world" rather than on findings primarily observed in clinical research. Read full article.
|
|
FDA has approved everolimus (Afinitor, Novartis) tablets to treat patients with progressive neuroendocrine tumors of pancreatic origin that cannot be removed by surgery or that have spread to other parts of the body. Read full article.
|
|
The National Lipid Association is kicking off a public health campaign about familial hypercholesterolemia on May 18. The start of the campaign, "FH: It's Relative—Know Your Family Cholesterol History," coincides with NLA's Annual Scientific Sessions in New York City. Read full article.
|
Top 5 Web Stories
- FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
- Metastatic breast cancer: A review of current and novel pharmacotherapy
- Belimumab: A B-lymphocyte stimulator inhibitor for-systemic lupus erythematosus
- Health reform controversies pose new challenges for drug plans and healthcare providers
- Intensive glycemic management leads to higher mortality in type 2 diabetes mellitus patient
 |
|
|
|
Contact Us |
Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
 Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
